Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 1063-

  Tanoglu, Alpaslan ^a   Karagoz, Ergenekon ^b  

^a Department of Gastroenterology ^*  (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; SORAFENIB;

HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TUMOR; LYMPHOCYTE; NEUTROPHIL; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; NEUTROPHILS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS;

EID: 84894646205     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.1063     Document Type: Letter

References (7)

1. Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M (2013). Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost, 19, 579.
2. Song T, Zhang W, Wu Q, Kong D, Ma W (2011). A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol, 23, 1233-8.
3. Stotz M, Gerger A, Eisner F, et al (2013). Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer, 109, 416-21.
4. Karaman M, Balta S, Ay SA, et al (2013). The comparative effects of valsartan and amlodipine on vWf Levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens, 35, 516-22.
5. Mulcahy MF (2005). Management of hepatocellular cancer. Curr Treat Options Oncol, 6, 423-35.
6. Qin LX, Tang ZY (2002). The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol, 8, 193-9.
7. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.